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Background: Hepcidin is classified as a type II acute phase protein; its production is a component of the innate
immune response to infections.
Objective: To evaluate the alterations of serum hepcidin in children during and following an acute febrile infection.
Materials and methods: 22 children with fever of acute onset (< 6 hours) admitted to the 2nd Department of
Pediatrics-University of Athens. Based on clinical and laboratory findings our sample formed two groups: the viral
infection group (13 children) and the bacterial infection group (9 children). Hepcidin, ferritin and serum iron
measurements were performed in all subjects.
Results: Serum hepcidin values did not differ notably between children with viral and bacterial infection, but a
significant reduction of hepcidin was noted in both groups post-infection.
Conclusion: Our study provides clinical pediatric data on the role of hepcidin in the face of an acute infection. In
our sample of children, hepcidin was found to rise during the acute infection and fall post-infection.
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Hepcidin is a cytokine-induced antimicrobial peptide
produced in the liver that principally regulates the
homeostasis of iron concentration. Although its produc-
tion can be induced by multiple stimuli, IL-6 is consid-
ered its dominant upregulator [1]. Thus hepcidin could
be classified as a type II acute phase protein. The
induction of hepcidin is a component of the innate
immune response to infections; it decreases extracellular
iron levels reducing iron availability to invading microor-
ganisms [2].
Most studies investigate the regulation and potential
roles of hepcidin in animal models [3,4]. Although
hepcidin plays a key role in the development of anaemia
associated with inflammation and chronic disease, there
are only a few clinical studies that examine hepcidin
alterations in acute or chronic infections. However, there
are not sufficient data in children to validate the use of* Correspondence: lydiakossiva@hotmail.com
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reproduction in any medium, provided the orhepcidin levels in clinical algorithms for the diagnosis of
acute infection.
The evaluation and treatment of children with fever
without a source is a challenging and controversial
clinical problem [5]. Although most well appearing
children with fever have benign viral illnesses, fever
might represent the first sign of occult bacteremia and
subsequent serious bacterial infection [6,7]. Discrimin-
ation based on clinical criteria has not been sufficient to
determine management [8].
A number of large prospective studies have established
criteria to accurately identify children warranting presump-
tive antibiotic therapy [9,10]. Traditional laboratory screen-
ing tests include total white blood cell count, absolute
neutrophil count, band to neutrophil ratio and C-reactive
protein [11-13]. The use of other acute phase reactants, such
as procalcitonin and IL-6, to ameliorate the sensitivity of the
screen resulted in increased use of antibiotics [14-17].
During an acute-phase reaction there are dramatic
changes in iron metabolism. Previous studies have
demonstrated differences in serum iron parameters in
children with acute bacterial versus viral infections [18].
We hypothesized that the comparison of hepcidin levelsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions would not yield significant differences enhancing
the role of hepcidin as an acute reactant protein. Thus
the aim of the present study was to evaluate the alter-
ations of serum hepcidin not only during the acute
febrile phase but also post-infection.
Materials and methods
This longitudinal study was conducted during a three-year
period between 2008 and 2011. Children of Greek origin
and nationality participated voluntarily in the study. In-
formed consent from parents was obtained in advance.
The Ethics Committee of our Hospital and the University
of Athens Medical School approved the research protocol.
Among 45 patients admitted to the 2nd Department
of Pediatrics-University of Athens, 22 children were
enrolled in the study. The subjects’ parents filled in a
detailed questionnaire, with specific attention any history
of anemia, chronic illness and folic acid or iron dietary
supplementation. Children receiving antibiotic treatment
or dietary iron supplementation as well as children with
history of chronic disease or other co-morbidities were
excluded from the study (18 patients). The remaining 5
febrile patients were also excluded since their infection
could not be classified as viral or bacterial. All participat-
ing children underwent thorough physical examination.
The study population consisted of 22 infants and chil-
dren (13 boys, mean age 28.06 ± 37.64 months, range 1
to 144 months) presenting with fever of acute onset
(< 6 hours). Full blood count with differential, routine
biochemical studies, C-reactive protein, hepcidin, ferritin
and serum iron measurements were performed in all
subjects at the time of presentation and 4 weeks later,
using standard methods by the same laboratory. The
hepcidin concentration samples were stored at -80°C for
5 to 10 months before analysis. Serum hepcidin-25
isoform measurements were performed by using a
specific ELISA kit (DRG INTERNATIONAL Inc. 1167
U.S Highway 22 East, Mountainside, NJ 07092 USA)
according to the manufacturer’s instructions [19].
Based on clinical and laboratory findings our sample
was divided into two groups: the viral infection group (13
children) and the bacterial infection group (9 children).
The discrimination between bacterial and viral infection
was based on the combination of positive blood or urine
culture along with C-reactive protein >40 mg/dl and
leukocytosis with neutrophilia (white blood cell count
>15.000/mm3, neutrophils >60%). The bacterial pathogens
isolated were: strep. pneumoniae, Esherichia Coli, Klebsi-
ella pneumoniae, staph aureus. The diagnosis of viral in-
fection was based on either positive polymerase chain
reaction (PCR) test or positive IgM antibodies for a spe-
cific viral agent (Epstein-Barr virus, cytomegalovirus, cox-
sackie virus, adenovirus). The clinical spectrum of febrileillnesses included upper or lower respiratory truct infec-
tions, urinary truct infections, occult bacteremia, gastro-
enteritis and cervical lymphadenitis.
Statistical analysis
All statistical analyses and data management were
performed using STATA for Windows v 8.5, (StataCorp,
Texas, USA, 2006). Data are expressed as Mean ± SD,
median. Our study population formed two groups, as
mentioned above, the viral infection and bacterial infec-
tion groups. Each study variable was measured during
the infection (variable 1) and after the infection (variable
2). Data between the two groups (variable X-viral group
vs. variable X-bacterial group) were compared using
non-parametric Mann-Whitney U test (independent
samples). Data within each group (variable X1 vs. vari-
able X2) were compared using non-parametric Wilcoxon
paired test (paired samples). We also calculated the dif-
ference between variable 1 and variable 2 as ΔvarX =
varX1-varX2 within each group and we compared these
differences between the two groups (ΔvarX-viral group
vs ΔvarX-bacterial group) using non-parametric Mann-
Whitney U test (independent samples). P < 0.05 was
considered significant.
Results
All study variables are presented in Table 1. Significant dif-
ferences are hereupon noted in detail. Serum hepcidin
values were not notably different between children with viral
and bacterial infection, but a significant reduction of
hepcidin was noted in both groups post-infection. Serum
ferritin values were similar among children belonging to the
two groups; however, serum iron levels were found signifi-
cantly lower only during the acute phase of bacterial infec-
tions. Within each group there were significant differences
in ferritin and iron levels observed during and after infec-
tion. Significant increases in hemoglobin and hematocrit
values were noted post-bacterial infection. The difference in
hematocrit (Δhct) was significantly greater in the bacterial
infection group as well as the difference in MCHC and re-
ticulocyte percentages. As expected, initial ESR values were
significantly higher in the bacterial infection group, resulting
in a greater difference of ΕSR (ΔESR) than in the viral infec-
tion group. Similar changes were observed in WBC and
neutrophil count, with higher initial values and greater dif-
ferences (ΔWBC and ΔN) found in children with bacterial
infections. Within each individual group initial lymphocyte
count value was significantly lower, while the difference in
monocyte count (ΔM) was significantly greater in the viral
infection group. Initial CRP value was considerably higher
in children with bacterial infections, leading to a greater dif-
ference (ΔCRP) in this group compared to the viral infection
group. Differences in platelet counts within each group were
significant.
Table 1 Characteristics of study population groups
Δvar = var1-var2 Viral infection (n = 13) Bacterial infection (n = 9) P*
Age (months) 22.8(±31.75), 8.5 (1 ~ 108) 35.66(±45.79), 18 (2 ~ 144)
Male gender (%) 7(53.85%) 6(66.67%)
Hepcidin1 90.52(±50.97), 79.44(11.42 ~ 210.18) 72.63(±39.95), 74.10(10.61 ~ 133.8) 0.48
Hepcidin2 53.18(±22.46), 46.17(27.12 ~ 100.73) 42.34(±28.83), 33.14(18.39 ~ 115.73) 0.12
Δhepcidin(1→ 2) 37.34(±59.89), 33.48(−89 ~ 178.74) 30.28(±38.25), 34.99(−39.44 ~ 87.61) 0.86
P** 0.033 0.05
Ferritin1 135.98(±106.36), 68.12(30.1 ~ 333.3) 160.01(±117.97), 106.5(73.57 ~ 457.3) 0.24
Ferritin2 50.66(±37.55), 34.5(14 ~ 160) 67.65(±54.01), 39.3(12.4 ~ 173) 0.5
Δferritin(1→ 2) 85.31(±106.86), 35.58(−25.9 ~ 292.58) 92.36(±142.80), 51.7(−69 ~ 421.95) 0.71
P** 0.0046 0.05
Serum iron1 29.69(±17.07), 28(9 ~ 69) 15.66(±4.58), 16(10 ~ 25) 0.015
Serum iron 2 47.69(±20.34), 46(21 ~ 76) 46.33(±27.83), 42(18 ~ 115) 0.61
ΔSerum iron (1→ 2) −18(±29.76), −17(−67 ~ 48) −30.66(±28.35), −24(−98 ~ 7) 0.24
P** 0.039 0.01
Hb1(gr/dl) 11.74(±1.91), 11.7(8.1 ~ 15.5) 11.4(±1.24), 11(10.2 ~ 13.7) 0.59
Hb2 (gr/dl) 11.93(±0.92), 11.8(10.6 ~ 13.7) 12.66(±0.87), 12.1(11.7 ~ 13.9) 0.065
ΔHb(1→ 2) −0.19(±1.63), −0.69(−2.5 ~ 3.7) −1.26(±0.95), −1.1(−3.4 ~ −0.19) 0.17
P** 0.46 0.007
Hct1 (%) 35.82(±5.62), 35.8(24.6 ~ 45.9) 34.5(±3.74), 32.9(30.3 ~ 41) 0.48
Hct2 (%) 35.30(±2.71), 35(32 ~ 40.5) 38.53(±2.48), 38.7(35.6 ~ 42) 0.01
Δhct(1→ 2) 0.51(±4.65), −0.70(−7.9 ~ 10.7) −4.03(±3.02), −3.1(−10.4 ~ −1) 0.01
P** 0.86 0.007
MCHC1 29.84(±1.58), 30(26 ~ 32.8) 29.36(±1.33), 29(27.5 ~ 31.3) 0.29
MCHC2 30.23(±1.20), 30(28 ~ 32) 30.36(±1.13), 30.2(28 ~ 32.1) 0.68
Δmchc(1→ 2) −0.38(±1.41), −0.5(−3 ~ 2) −1.0(±1.15), −1(−3 ~ 0.5) 0.34
P** 0.32 0.028
reticulocytes1(%) 1.21(±0.66), 1(0.5 ~ 2.7) 1.6(±0.64), 1.5(0.6 ~ 2.4) 0.16
reticulocytes 2 (%) 0.86(±0.35), 0.8(0.3 ~ 1.4) 0.8(±0.36), 0.7(0.3 ~ 1.6) 0.66
Δreticulocytes (1→ 2) 0.35(±0.74), 0.3(−0.8 ~ 2.1) 0.8(±0.64), 0.6(0–1.7) 0.13
P** 0.10 0.012
ESR1 (mm/1 h) 17.38(±8.11), 15(5 ~ 31) 37.66(±14.04), 38(19 ~ 70) 0.0007
ESR2 (mm/1 h) 11.38(±8.7), 9(4 ~ 35) 12.44(±8.5), 10(4 ~ 30) 0.68
ΔESR(1→ 2) 6.0(±12.32), 3(−15 ~ 26) 25.22(±12.36), 26(8 ~ 49) 0.0033
P** 0.1 0.007
WBC1/mm3 10205(±3806), 10100(4200 ~ 18200) 23133(±13813), 17400(9300 ~ 50100) 0.005
WBC2/mm3 10100(±3003), 8900(6000 ~ 16800) 10855(±5008), 10400(4700 ~ 21100) 0.86
Δwbc(1→ 2) 115(±4306), 200(−6300 ~ 9700) 12277(±12920), 7700(−4000 ~ 34100) 0.016
P** 0.94 0.02
N1 (%) 47.38(±24.59), 54(11 ~ 89) 69.55(±16.43), 66(40 ~ 89) 0.02
N2 (%) 37.07(±11.62), 35(21 ~ 63) 37.17(±15.87), 41(10 ~ 55) 0.73
ΔN(1→ 2) 10.3(±18.19), 16(−24 ~ 33) 37.37(±18.42), 37(−1 ~ 56) 0.01
P** 0.063 0.0109
L1 (%) 37.3(±23.08), 33(5 ~ 72) 19.88(±10.44), 23(6 ~ 33) 0.08
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Table 1 Characteristics of study population groups (Continued)
L2 (%) 49.61(±14.20), 52(27 ~ 72) 48.63(±18.18), 45(32 ~ 82.5) 0.78
ΔL(1→ 2) −12.3(±18.71), −17(−39 ~ 24) −28.74(±16.85), −28(−55.5 ~ −7) 0.065
P** 0.042 0.007
M1 (%) 12.38(±5.79), 12(6 ~ 24) 8.66(±5.52), 6(3 ~ 20) 0.069
M2 (%) 8.23(±2.80), 7(4 ~ 13) 10.03(±3.45), 10(6 ~ 16) 0.19
ΔM(1→ 2) 4.15(±6.4), 2(−4 ~ 18) −1.36(±6.39), −3(−10 ~ 10) 0.034
P** 0.072 0.4
CRP1 (mg/dl) 17.07(±24.69), 12(0 ~ 93) 100.88(±59.50), 92(24 ~ 178) 0.0006
CRP2 (mg/dl) 4.57(±5.48), 1(0 ~ 17) 5.11(±9.51), 2(0 ~ 30) 0.91
Δcrp(1→ 2) 12.5(±23.08), 7(−9 ~ 82) 95.77(±64.87), 90.5(−6 ~ 173) 0.0037
P** 0.022 0.0109
PLT1 /mm3 382923(±162607), 335000(191000 ~ 758000) 465444(±162687), 438000(215000 ~ 709000) 0.19
PLT2 /mm3 275538(±63602), 278000(198000 ~ 403000) 302555(±48844), 303000(230000 ~ 383000) 0.25
ΔPLT(1→ 2) 107384(±137673), 44000(−84000 ~ 355000) 162888(±132197), 120000(−41000 ~ 326000) 0.3
P** 0.015 0.0109
P* Mann-Whitney U test.
P** Wilcoxon paired test.
Data are expressed as mean (±SD), median.
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Our study provides clinical pediatric data on the role of
hepcidin in the face of an acute infection. In our sample
of children with viral and bacterial infections, hepcidin
was found to rise during the acute infection and fall
post-infection.
Hepcidin is a 25-amino acid peptide synthesized by hepa-
tocytes, secreted into the bloodstream and cleared from the
circulation by the kidneys. It regulates the levels of circulat-
ing iron by controlling the absorption of dietary iron and
the release of iron from macrophages and hepatocytes.
Hepcidin synthesis is regulated by both physiologic and
pathologic mechanisms. In peripheral blood leads in de-
crease in hepcidin concentration In hypoxia, iron deficiency,
anemia or ineffective erythropoiesis, increased iron demand
in the peripheral blood leads to a decrease in hepcidin
concentation. The latter results in increased absorption of
iron from the intestine and increased release from iron-
storing cells by binding, internalization and degradation of
the cellular iron efflux molecule, ferroportin [20].
On the contrary, infection, chronic inflammation and iron
overload result in increases of hepcidin concentration and
subsequent decreases in circulating iron; in hereditary
hemochromatosis a mutated hepcidin gene results in defi-
cient excretion of the molecule leading to iron
accumulation.
Most studies examining the role of hepcidin as an acute
phase protein are based on in vitro and animal models.
Specifically, hepcidin has been well described as a hepatic
acute phase protein in laboratory studies similarly to fer-
ritin. Ferritin rises during acute infections resulting in un-
reliable measurements as an iron parameter. Murinemodels indicate that hepcidin is a component of the in-
nate immune response to acute infection with anti-
inflammatory properties and a potential marker of billiary
stress [21,22]. Experimental deliberate exposure to bacter-
ial agents in salmon and rats has demonstrated the up
regulation of hepcidin [23,24].
Limited research data from adult populations attempt to
elucidate the role of hepcidin in the common cold, iron me-
tabolism disorders, chronic kidney disease, chronic hepatitis
C and kidney transplant recipients [25-27]. In an adult pa-
tient population study group, hepcidin was demonstrated as
a potentially useful marker that reflects the degree of billiary
inflammation in cholecystitis and primary sclerosing cholan-
gitis (PSC) - associated bacterial infection. To the best of our
knowledge, there are only two studies examining the role of
serum hepcidin during chronic infections in pediatric popu-
lations. One showed a correlation of increased hepcidin
levels with asymptomatic malarial parasitemia (P. falciparum
and P. vivax), despite the absence of a measurable acute
phase response [28]. The second failed to demonstrate sig-
nificant alterations of hepcidin levels in children with chronic
gastrointestinal infections (H. pylori and helminthes) [29].
The main limitation of our study was the small size of
sample. However, since weak statistical significance was
achieved, a larger sample is needed to clarify the changes
in hepcidin levels. The comparison of its levels in chil-
dren convalescing from bacterial and viral infections did
not yield significant differences. Interestingly, low levels
of serum iron were shown in bacterial infections. These
findings generate thoughts about the existence of other
biological parameters involved in the regulation of iron
metabolism during acute infection.
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The present study provides preliminary data on the role
of hepcidin as an acute reaction marker in febrile chil-
dren. Further studies are needed to clarify our findings,
ideally in a larger sample of febrile children. In addition
other biological parameters involved in iron metabolism
could be investigated.
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